Health Condition 1: C159- Malignant neoplasm of esophagus, unspecified Health Condition 2: C37- Malignant neoplasm of thymus Health Condition 3: C349- Malignant neoplasm of unspecifiedpart of bronchus or lung
Conditions
Interventions
Intervention1: NIL: NIL
Sponsors
Tata Memorial Hospital
Eligibility
Inclusion criteria
Inclusion criteria: 1. Pathological or cytological evidence of malignancy 2. Patients treated with thoracic radiotherapy ± chemotherapy (neoadjuvant, adjuvant, and definitive radiation) 3. Patients willing to sign the written informed consent 4. Patients willing for follow up
Exclusion criteria
Exclusion criteria: 1. Age 2. Reirradiation to the thoracic area where cardiac structures already received a significant dose 3. Life expectancy of less than 6 months
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To identify the high-risk cohort of patients for cardiac toxicity in patients treated with Radiotherapy ± Chemotherapy for thoracic malignancies AND To evaluate any grade cardiac toxicities in thoracic cancer patients treated with definitive Radiotherapy ± Chemotherapy Timepoint: Baseline, 6 months, 12 months and yearly thereafter | — |
Secondary
| Measure | Time frame |
|---|---|
| Correlation of Cardiac Biomarkers with Cardiac Toxicity and Survival in Severely high-risk patientsTimepoint: 6 months, 12 months and yearly thereafter;Cumulative Incidence of = Grade 3 Cardiac ToxicityTimepoint: 6 months, 12 months and yearly thereafter;Number of patients requiring Cardiac InterventionTimepoint: 6 months, 12 months and yearly thereafter;To assess the impact of dosimetric parameters of the whole heart and its substructuresTimepoint: 6 months, 12 months and yearly thereafter;To identify radiological and functional imaging correlates of cardiac toxicityTimepoint: 6 months, 12 months and yearly thereafter | — |
Countries
India
Contacts
Public ContactAnil Tibdewal
Tata Memorial Hospital
Outcome results
None listed